Indeed, in a tissue assessment of SARC-028 trial patients, Keung et al. reported that the presence of CD3+CD8+PD-1+ T cells and tumor-associated macrophages (TAMs) expressing PD-L1 corresponded with response to ICB and improved progression-free survival [61]. This evidence concerns the gene CD8A and neoplasm.